Traditional means of funding private companies in the life science industry have changed forever. Venture capital is no longer a logical choice for raising capital to fund pre-clinical programs, just as it’s no long practical or acceptable to spend vast amounts of cash to advance such research. The San Diego Venture Group has assembled a panel of experienced investors to explore how companies in the life science industry can seek to accomplish their goals with—or without—traditional VC funding. Registration begins at 7 a.m., or register online here.